17336-10-6 Usage
Explanation
This is the chemical name of the compound, which is derived from its structural formula and functional groups.
Explanation
These are the common names for the compound, which are more widely recognized and used in everyday language.
Explanation
This indicates that the compound belongs to a specific group of organic compounds, which share a common structure and properties.
Explanation
This describes the primary therapeutic application of the compound, which is to alleviate pain and lower body temperature in cases of fever.
Explanation
This explains how the compound exerts its therapeutic effect, by preventing the formation of certain chemicals in the body that are responsible for pain and inflammation.
Explanation
This highlights other potential health benefits of the compound, beyond its primary use as a pain reliever and fever reducer.
Explanation
These are potential adverse effects that may occur as a result of using the compound, which can cause harm to the user.
Explanation
This advises users to seek professional medical advice before using the compound, in order to minimize the risk of side effects and ensure its safe and effective use.
Chemical class
Benzoic acids and derivatives
Main use
Pain reliever and fever reducer
Mechanism of action
Inhibits production of pain and inflammation-causing substances
Additional use
Reducing risk of heart attacks and strokes, treating circulatory conditions
Side effects
Stomach bleeding and ulcers
Caution and guidance
Use under the supervision of a healthcare professional
Check Digit Verification of cas no
The CAS Registry Mumber 17336-10-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,3,3 and 6 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 17336-10:
(7*1)+(6*7)+(5*3)+(4*3)+(3*6)+(2*1)+(1*0)=96
96 % 10 = 6
So 17336-10-6 is a valid CAS Registry Number.
17336-10-6Relevant articles and documents
Demonstrating Ligandability of the LC3A and LC3B Adapter Interface
Hartmann, Markus,Huber, Jessica,Kramer, Jan S.,Heering, Jan,Pietsch, Larissa,Stark, Holger,Odadzic, Dalibor,Bischoff, Iris,Fürst, Robert,Schr?der, Martin,Akutsu, Masato,Chaikuad, Apirat,D?tsch, Volker,Knapp, Stefan,Biondi, Ricardo M.,Rogov, Vladimir V.,Proschak, Ewgenij
, p. 3720 - 3746 (2021/05/04)
Autophagy is the common name for a number of lysosome-based degradation pathways of cytosolic cargos. The key components of autophagy are members of Atg8 family proteins involved in almost all steps of the process, from autophagosome formation to their selective fusion with lysosomes. In this study, we show that the homologous members of the human Atg8 family proteins, LC3A and LC3B, are druggable by a small molecule inhibitor novobiocin. Structure-activity relationship (SAR) studies of the 4-hydroxy coumarin core scaffold were performed, supported by a crystal structure of the LC3A dihydronovobiocin complex. The study reports the first nonpeptide inhibitors for these protein interaction targets and will lay the foundation for the development of more potent chemical probes for the Atg8 protein family which may also find applications for the development of autophagy-mediated degraders (AUTACs).